Ticker Hub
GH — AI Analysis & Sentiment
6 recent AI-generated analyses for GH. Sentiment and confidence insights updated continuously.
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
The ACS recommendation for Guardant Health's Shield test is a significant catalyst, expanding its market for colorectal cancer screening. This endo...
May 27, 2026FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health's FDA approval for its expanded Guardant360 Liquid CDx significantly strengthens its market position in oncology diagnostics. This ...
May 20, 2026Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health's strong Q1 performance and significantly raised 2026 guidance, driven by accelerating test volumes, present a bullish opportunity....
May 8, 2026Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
Guardant Health's launch of its Shield MCD test in Asia via a partnership with Manulife marks a strategic entry into a large, underserved market. T...
Mar 16, 2026Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics
Guardant Health's partnership with Quest Diagnostics for its Shield test creates a significant long-term growth opportunity by dramatically expandi...
Mar 11, 2026Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Guardant Health's strong revenue growth and improving financial metrics are mispriced by the market, creating a bullish opportunity. The company's ...
Feb 19, 2026